Form 4: Charles River Laboratories Executive Reports Stock Transactions

Shannon M. Parisotto, a CEVP at Charles River Laboratories, reported transactions involving company stock, including the acquisition of shares through performance-based awards and a transfer to Karpathos Investments LLC.

Summary

• Shannon M. Parisotto, a CEVP at Charles River Laboratories, filed a Form 4 detailing changes in their beneficial ownership of company stock.
• On January 31, 2025, Parisotto acquired 1,758 shares of common stock as a result of performance share unit awards granted on May 27, 2022.
• Also on January 31, 2025, 471 shares were disposed of to cover tax obligations at a price of $165.57 per share.
• Additionally, 694 shares were transferred to Karpathos Investments LLC, an entity through which Parisotto indirectly holds shares.
• Following these transactions, Parisotto directly owns 8,999 shares and indirectly owns 27,223 shares through Karpathos Investments LLC.

Sentiment

Score: 6

Explanation: The document is neutral, detailing routine stock transactions. There are no significant positive or negative implications for the company's performance or outlook.

Positives

• The acquisition of 1,758 shares indicates that performance goals were met, which is a positive sign for the company's performance.
• The disclosure of these transactions provides transparency to investors.

Negatives

• The disposal of 471 shares to cover tax obligations could be seen as a minor negative, although it is a common practice.

Risks

• There are no specific risks mentioned in this document, as it primarily details stock transactions by an executive.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It does not indicate any specific trends or competitive actions within the industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions reported are typical for executives who receive stock-based compensation.

Related Party Transactions

• The transfer of 694 shares to Karpathos Investments LLC is a related party transaction.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine executive compensation and tax obligations.
• The disclosure provides transparency to all stakeholders.

Key Dates

Keywords

stock transactions, beneficial ownership, Form 4, executive compensation, performance share units, Charles River Laboratories, CRL, insider trading